Associated Papers
Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenias of Undetermined Significance: 2026 Update on Clinical Associations and Management Recommendations.
Mangaonkar AA et al.
American Journal of Hematology, 2026
Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression.
Wedge E et al.
Molecular Oncology, 2026
SF3B1K700E rewires splicing of cell cycle regulators.
Baker M et al.
Rna (new York, N.y.), 2026
NOTCH1 and SF3B1 mutations in chronic lymphocytic leukemia with their clinical associations.
Ahmed VR et al.
Leukemia & Lymphoma, 2026
Mesangial sclerosing glomerulopathy following luspatercept treatment - a case report.
Bataille S et al.
Bmc Nephrology, 2026
BESTish: A Diffusion-Approximation Framework for Inferring Selection and Mutation in Clonal Hematopoiesis.
Wang RY et al.
Biorxiv : the Preprint Server for Biology, 2026
B-cell acute lymphoblastic leukemia following myelodysplastic syndromes: a case report and literature review.
Ding H et al.
Journal of Hematopathology, 2026
SF3B1 mutations in spliceosome-driven tumorigenesis: From splicing dysregulation to signaling network rewiring and therapeutic targeting.
Yang T et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2026
Clinical Characteristics and Molecular Profiling of SF3B1-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice.
Wang RR et al.
International Journal of Molecular Sciences, 2026
Splicing-driven post-translational dysregulation: a new frontier for precision cancer medicine and immunotherapy.
Alatawi S
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
De novo variants in the splicing factor gene SF3B1 are associated with neurodevelopmental disorders.
Uguen K et al.
Nature Communications, 2026
A framework for the molecular identification of CHIP for clinical research.
Harraka P et al.
Hgg Advances, 2026
SF3B1 Phosphorylation Prompts U2AF2 Dissociation for Widespread Control of pre-mRNA Splicing.
Kirchhoff CL et al.
Biorxiv : the Preprint Server for Biology, 2026
Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.
Komrokji RS et al.
American Journal of Hematology, 2026
Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort.
Lu X et al.
Biomedicines, 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026
Targeting EZH2 Oncogenic Splicing: Decoding the Regulatory Network and Antisense Correction.
Islam MR et al.
Biorxiv : the Preprint Server for Biology, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Association of ASXL1 and RUNX1 Variants with Splenomegaly in Myelodysplastic Syndromes Based on Next-generation Sequencing and Computed Tomography Data: A Retrospective Study.
Huh Y et al.
Annals of Laboratory Medicine, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know.
Perrone S et al.
Journal of Clinical Medicine, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Multipurpose RNA maturation factors dysregulate multiple mRNA processing steps simultaneously and provide new therapeutic opportunities.
Paira S et al.
Rna Biology, 2025
Precursor RNA structural patterns at SF3B1 mutation sensitive cryptic 3' splice sites.
Herbert A et al.
Rna Biology, 2025
Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets.
Zhu ZM et al.
Medcomm, 2025
Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy.
Lv YH et al.
Biomarker Research, 2025
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.
Krigstein M et al.
Annals of Laboratory Medicine, 2025
An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome.
Chen L et al.
Nature Communications, 2025
Somatic Mutation Profiling and Therapeutic Landscape of Breast Cancer in the MENA Region.
Velayutham D et al.
Cells, 2025
Novel and emerging therapeutic strategies for clonal haematopoiesis.
Hosseini M et al.
Haematologica, 2025
BRD9 depletion-mediated ALOX5 upregulation via chromatin dysregulation induces ferroptosis in SF3B1-mutant hematopoiesis.
Saika W et al.
International Journal of Hematology, 2025
Generative Design of Cell Type-Specific RNA Splicing Elements for Programmable Gene Regulation.
Chen XD et al.
Biorxiv : the Preprint Server for Biology, 2025
SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.
Thier J et al.
Leukemia, 2025
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
A single nucleotide polymorphism in the TCL1A promoter is not protective in patients with germ line RUNX1-FPD.
Kajdic A et al.
Blood Neoplasia, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Tantawy SI et al.
Blood Cancer Journal, 2025
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications.
Steinauer N et al.
Current Hematologic Malignancy Reports, 2025
High Prevalence of Potential Molecular Therapeutic Targets in Poorly Differentiated Thyroid Carcinoma.
Zambelli V et al.
Endocrine Pathology, 2025